Loading clinical trials...

COMPLETEDNA

A Survivorship Care Plan and Embedded Navigation Tool

Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients With Prostate Cancer Undergoing Curative-Intent Radiotherapy With Concurrent Androgen Deprivation Therapy (ADT)

NCT03424837•Duke University

View on ClinicalTrials.gov

Summary

This is a parallel group, multisite prospective clinical study. The purpose of this study is to evaluate whether ASCENT enables patients to adhere to the survivorship guidelines and improves coordination of care to address patient needs.

Eligibility

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed diagnosis of prostate adenocarcinoma
•Age ≥18 years
•Receiving curative intent radiotherapy for prostate cancer (Note: post-operative radiotherapy \[i.e., "adjuvant" or "salvage radiotherapy subsequent to prostatectomy\] is allowed.)
•Subjects will be enrolled within two weeks prior to and two weeks after the final fraction of radiotherapy.
•Receiving androgen deprivation therapy (ADT) for a duration of ≥3 consecutive months as follows:
•* GnRH agonist or antagonist (medical castration), with or without an anti-androgen (i.e., bicalutamide, flutamide, nilutamide, etc.), OR
•* Bilateral orchiectomy (surgical castration)
•Technology requirement: candidates must have access to the internet
•Able to understand and willing to sign a written informed consent document.
•Able to speak and understand English, in the opinion of the treating physician.

Exclusion Criteria

•Significant concurrent medical or psychiatric condition that would interfere with the patient's ability to abide by the study protocol or cooperate fully with the protocol requirements, including completion of survey and assessment

Locations (6)

H. Lee Moffitt Cancer Center & Research Institute

Tampa, Florida, United States

Emory University & Winship Cancer Institute

Atlanta, Georgia, United States

Johns Hopkins School of medicine & Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

UNC Lineberger Cancer Center

Chapel Hill, North Carolina, United States

Duke Cancer Institute

Durham, North Carolina, United States

Key Dates

Start Date

January 11, 2019

Primary Completion Date

November 24, 2020

Completion Date

November 24, 2020

Last Updated

July 29, 2021

Enrollment

ACTUAL participants

Conditions

Prostate Cancer

Interventions

ASCENT

BEHAVIORAL

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE2

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06842498

Metastatic Castration-Resistant Prostate Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Survivorship Care Plan and Embedded Navigation Tool

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC